Rajanikanth Madabushi

2.6k total citations
58 papers, 1.8k citations indexed

About

Rajanikanth Madabushi is a scholar working on Pediatrics, Perinatology and Child Health, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Rajanikanth Madabushi has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pediatrics, Perinatology and Child Health, 19 papers in Economics and Econometrics and 14 papers in Statistics and Probability. Recurrent topics in Rajanikanth Madabushi's work include Pharmaceutical studies and practices (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Statistical Methods in Clinical Trials (14 papers). Rajanikanth Madabushi is often cited by papers focused on Pharmaceutical studies and practices (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Statistical Methods in Clinical Trials (14 papers). Rajanikanth Madabushi collaborates with scholars based in United States, Germany and United Kingdom. Rajanikanth Madabushi's co-authors include Yaning Wang, Hao Zhu, Issam Zineh, Shiew‐Mei Huang, S. Hariharan, Hartmut Derendorf, B Booth, Qi Liu, Eva Gil Berglund and Julie Bullock and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and CHEST Journal.

In The Last Decade

Rajanikanth Madabushi

57 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rajanikanth Madabushi United States	19	443	333	285	277	274	58	1.8k
Thomas Kerbusch Netherlands	22	411 0.9×	359 1.1×	347 1.2×	165 0.6×	134 0.5×	47	1.9k
Hao Zhu United States	18	315 0.7×	177 0.5×	141 0.5×	295 1.1×	129 0.5×	66	1.3k
Bart A. Ploeger Netherlands	26	630 1.4×	498 1.5×	364 1.3×	145 0.5×	169 0.6×	67	2.3k
Felix W. Frueh United States	25	799 1.8×	654 2.0×	206 0.7×	165 0.6×	132 0.5×	50	2.2k
Alexander Staab Germany	23	445 1.0×	175 0.5×	541 1.9×	156 0.6×	376 1.4×	54	2.0k
Jörg Lippert Germany	28	630 1.4×	755 2.3×	472 1.7×	273 1.0×	244 0.9×	75	3.0k
Dale P. Conner United States	24	374 0.8×	415 1.2×	262 0.9×	395 1.4×	207 0.8×	56	2.7k
Martin Bergstrand Sweden	17	311 0.7×	235 0.7×	425 1.5×	175 0.6×	110 0.4×	38	2.5k
Thomas M. Polasek Australia	25	289 0.7×	678 2.0×	340 1.2×	126 0.5×	142 0.5×	69	1.6k
Henning Blume Germany	25	338 0.8×	278 0.8×	168 0.6×	177 0.6×	143 0.5×	89	2.1k

Countries citing papers authored by Rajanikanth Madabushi

Since Specialization

Citations

This map shows the geographic impact of Rajanikanth Madabushi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajanikanth Madabushi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajanikanth Madabushi more than expected).

Fields of papers citing papers by Rajanikanth Madabushi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajanikanth Madabushi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajanikanth Madabushi. The network helps show where Rajanikanth Madabushi may publish in the future.

Co-authorship network of co-authors of Rajanikanth Madabushi

This figure shows the co-authorship network connecting the top 25 collaborators of Rajanikanth Madabushi. A scholar is included among the top collaborators of Rajanikanth Madabushi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajanikanth Madabushi. Rajanikanth Madabushi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nugent, Bridget M., Anuradha Ramamoorthy, Jennifer R. Pippins, et al.. (2025). Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023. Clinical Pharmacology & Therapeutics. 117(6). 1627–1631. 1 indexed citations

Liu, Jiang, Yuching Yang, Jogarao Gobburu, et al.. (2025). Considerations for Regulatory Reusability of Dynamic Tools in the New Drug Development. Pharmaceutical Research. 42(5). 765–771. 3 indexed citations

Wang, Yow‐Ming, Ólanrewaju O. Okusanya, Bilal Abuasal, et al.. (2024). Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins. Clinical Pharmacology & Therapeutics. 115(3). 440–451. 6 indexed citations

Madabushi, Rajanikanth, et al.. (2024). The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway. Clinical Pharmacology & Therapeutics. 116(2). 278–281. 9 indexed citations

Ridge, Sarah T., Xinning Yang, Rajanikanth Madabushi, & Anuradha Ramamoorthy. (2024). Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023. The Journal of Clinical Pharmacology. 65(3). 378–388. 1 indexed citations

Fang, Lanyan, Rajanikanth Madabushi, Hao Zhu, et al.. (2024). Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. Clinical Pharmacology & Therapeutics. 117(1). 116–129. 3 indexed citations

Bi, Youwei, et al.. (2024). Potential Bias Evaluation of Conventional Exposure-Response Analysis.

Vaidyanathan, Jayabharathi, et al.. (2023). Predicting Food Effects on Oral Extended-Release Drug Products: A Retrospective Evaluation. The AAPS Journal. 25(3). 33–33. 2 indexed citations

Abulwerdi, Gelareh, et al.. (2023). Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020. Clinical and Translational Science. 16(10). 2046–2057. 1 indexed citations

10.

Madabushi, Rajanikanth, Paul Seo, Liang Zhao, Million A. Tegenge, & Hao Zhu. (2022). Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making. Pharmaceutical Research. 39(8). 1669–1680. 102 indexed citations

11.

Ramamoorthy, Anuradha, et al.. (2022). Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives. Clinical Pharmacology & Therapeutics. 113(3). 528–535. 14 indexed citations

12.

Madabushi, Rajanikanth, Richard Graham, Kellie S. Reynolds, et al.. (2021). Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting. Clinical Pharmacology & Therapeutics. 110(2). 285–288. 6 indexed citations

13.

Guinn, Daphne, et al.. (2020). Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation. Therapeutic Innovation & Regulatory Science. 54(6). 1363–1371. 1 indexed citations

14.

Maxfield, Kimberly, Daniel González, Qi Liu, et al.. (2020). Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World Setting. Clinical Pharmacology & Therapeutics. 109(1). 25–28. 16 indexed citations

15.

Madabushi, Rajanikanth, Jeffry Florian, Anuradha Ramamoorthy, et al.. (2020). Role of Guidance and Policy in Enhancing the Impact of Clinical Pharmacology in Drug Development, Regulation, and Use. Clinical Pharmacology & Therapeutics. 108(4). 710–715. 1 indexed citations

16.

Madabushi, Rajanikanth, Michael Pacanowski, David G. Strauss, et al.. (2019). The US Food and Drug Administration's Model‐Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact. Clinical Pharmacology & Therapeutics. 106(1). 74–78. 25 indexed citations

17.

Jin, Yuyan, Robert R. Bies, Marc R. Gastonguay, et al.. (2014). Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study. Journal of Pharmacokinetics and Pharmacodynamics. 41(6). 693–704. 3 indexed citations

18.

Hariharan, S. & Rajanikanth Madabushi. (2011). Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment. The Journal of Clinical Pharmacology. 52(S1). 119S–25S. 73 indexed citations

19.

Zhao, Ping, Joseph A. Grillo, Julie Bullock, et al.. (2010). Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review. Clinical Pharmacology & Therapeutics. 89(2). 259–267. 402 indexed citations

20.

Burkhardt, Olaf, et al.. (2006). Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scandinavian Journal of Infectious Diseases. 38(10). 904–908. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact